Genmab ADR (NASDAQ: GMAB) has a price-to-earnings ratio that is above its average at 13.05x. The stock has a 36-month beta value of 0.96. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for GMAB is 614.74M, and at present, short sellers hold a 0.39% of that float. On June 12, 2025, the average trading volume of GMAB was 1.44M shares.
GMAB) stock’s latest price update
The stock of Genmab ADR (NASDAQ: GMAB) has increased by 1.65 when compared to last closing price of 22.63. Despite this, the company has experienced a 5.47% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
GMAB’s Market Performance
GMAB’s stock has risen by 5.47% in the past week, with a monthly rise of 19.13% and a quarterly rise of 15.25%. The volatility ratio for the week is 1.58% while the volatility levels for the last 30 days are 1.65% for Genmab ADR The simple moving average for the past 20 days is 7.80% for GMAB’s stock, with a 5.44% simple moving average for the past 200 days.
Analysts’ Opinion of GMAB
Leerink Partners gave a rating of “Outperform” to GMAB, setting the target price at $27 in the report published on February 13th of the current year.
GMAB Trading at 12.79% from the 50-Day Moving Average
After a stumble in the market that brought GMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.45% of loss for the given period.
Stock Fundamentals for GMAB
Current profitability levels for the company are sitting at:
- 0.34 for the present operating margin
- 0.95 for the gross margin
The net margin for Genmab ADR stands at 0.37. The total capital return value is set at 1.04. Equity return is now at value 22.69, with 19.07 for asset returns.
Based on Genmab ADR (GMAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at 45.77. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 63.44.
Currently, EBITDA for the company is 7.39 billion with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 4.96. The receivables turnover for the company is 22.65for trailing twelve months and the total asset turnover is 2.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
To sum up, Genmab ADR (GMAB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
